Five-year follow-up in resectable stage II–IIIB NSCLC (n=797): perioperative pembrolizumab plus neoadjuvant chemotherapy vs placebo gave 5-year EFS of 49.9% vs 26.5% (HR 0.58) and 5-year OS of 64.6% vs 53.6% (HR 0.74), with no quality-of-life detriment.
RCTn = 797
Wakelee et al. Five-year outcomes of perioperative pembrolizumab for early-stage non-small-cell lung cancer from the randomized KEYNOTE-671 study